These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1420749)

  • 61. The mode of action alginic acid compound in the reduction of gastroesophageal reflux.
    Malmud LS; Charkes ND; Littlefield J; Reilley J; Stern H; Rosenberg R; Fisher RS
    J Nucl Med; 1979 Oct; 20(10):1023-8. PubMed ID: 231639
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments.
    Strugala V; Dettmar PW; Sarratt K; Sykes J; Berry P; Thomas E
    J Int Med Res; 2010; 38(2):449-57. PubMed ID: 20515559
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy.
    Lindow SW; Regnéll P; Sykes J; Little S
    Int J Clin Pract; 2003 Apr; 57(3):175-9. PubMed ID: 12723718
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
    Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
    Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon® Advance: how we do it.
    Lieder A; Issing W
    Clin Otolaryngol; 2011 Dec; 36(6):583-7. PubMed ID: 22212545
    [No Abstract]   [Full Text] [Related]  

  • 67. Cisapride treatment for gastro-oesophageal reflux in children.
    Augood C; MacLennan S; Gilbert R; Logan S
    Cochrane Database Syst Rev; 2000; (3):CD002300. PubMed ID: 10908549
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
    [No Abstract]   [Full Text] [Related]  

  • 69. Gastric pH and endoscopic appearance after Algicon administration.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():25-8; discussion 35-6. PubMed ID: 2511920
    [No Abstract]   [Full Text] [Related]  

  • 70. The alginate raft: a scintigraphic evaluation.
    McKay AP; Wraight EP; Hunter JO
    Br J Clin Pract Suppl; 1989 Feb; 66():20-4; discussion 35-6. PubMed ID: 2511919
    [No Abstract]   [Full Text] [Related]  

  • 71. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
    Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
    Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
    [No Abstract]   [Full Text] [Related]  

  • 72. [Gastro-esophageal reflux. Treatment with Gaviscon].
    Ferrier JP; Chevrel B
    Med Chir Dig; 1978; 7(1):73-6. PubMed ID: 642629
    [No Abstract]   [Full Text] [Related]  

  • 73. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1524-1533. PubMed ID: 28464343
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trial of gaviscon in the treatment of gastro-oesophageal reflux of infancy.
    Weldon AP; Robinson MJ
    Aust Paediatr J; 1972 Oct; 8(5):279-81. PubMed ID: 4349107
    [No Abstract]   [Full Text] [Related]  

  • 75. Non-invasive detection of gastro-oesophageal reflux using an ambulatory system.
    Washington N; Moss HA; Washington C; Greaves JL; Steele RJ; Wilson CG
    Gut; 1993 Nov; 34(11):1482-6. PubMed ID: 8244128
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effect of Algicon suspension on postprandial esophageal pH in acid gastro-esophageal reflux].
    Ducrotté P; Fournet J; Gosselin A; de Maynard C
    Gastroenterol Clin Biol; 1990; 14(2):190-1. PubMed ID: 2328889
    [No Abstract]   [Full Text] [Related]  

  • 77. Commentary: revisiting the past--does it hold the key to the future treatment of refractory GERD?
    Katz PO; Schnoll-Sussman F
    Aliment Pharmacol Ther; 2013 Jul; 38(2):202-3. PubMed ID: 23772900
    [No Abstract]   [Full Text] [Related]  

  • 78. [Therapeutic procedures in gastroesophageal reflux disease].
    Tytgat GN
    Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
    Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
    J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gaviscon: not always entirely safe!
    Shenvi A
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23329718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.